Introduction
Articular cartilage is a highly specialised tissue that has remarkable ability to resist mechanical loading, and it plays a vital role in the human natural joints. Unfortunately, unlike other tissues, articular cartilage is unable to self-repair and regenerate due to its aneural, avascular and alymphatic nature 1 . Once damage has been done, it is usually irreparable and will subsequently progress to osteoarthritis, which is a debilitating degenerative condition that affects millions of people in the world. The current surgical treatments include osteochondral autograft transplantation, mosaicplasty, microfractures and autologous chondrocytes implantation (ACI), the choice of which to use mainly depends on the size of the lesion, age of the patient and availability of the treatment. Although these techniques have variable success rate, some long-term follow-ups have reported unsatisfactory outcomes [2] [3] [4] [5] . The goal standard in treating articular cartilage disease is to restore the joint surface with suitable tissue, provide pain relief and most importantly to put a halt in further joint degeneration. To date, it still remains a challenge for surgeons and researchers to create a replacement that bears a resemblance to the native cartilage in terms of structure and its composition. This easy to assimilate paper will help multiple audiences to understand the significance and potential of the research by addressing currently available tissue engineering strategies and progresses in the field of articular cartilage restoration, with respect to cell sources, biomaterial scaffolds and growth factors.
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies. Animal care was in accordance with the institution guidelines.
Over the past two decades, the field of articular cartilage restoration has witnessed a great advancement and expansion in the development of cartilage tissue engineering. Made possible by Langer and Vacanti 6 , cartilage tissue engineering aims to repair and restore the functional and mechanical property of a native articular cartilage. Due to the high demand, a wide range of tissue engineering-based strategies are currently being established and investigated clinically as an option to the routinely used techniques. The tissue engineering standpoint is achieved by a combination of three major chords which include: suitable cell source, biomaterial scaffolds and signalling molecules.
Cell source
In order to gain optimum articular cartilage repair, the ideal cell source should be easily accessible and maintained as well as capable to synthesise rich extra-cellular matrix components, mainly the type II collagen and aggrecan. The highly potential cell sources in articular cartilage engineering are chondrocytes and stem cells.
Chondrocytes
Chondrocyte-based cell therapy holds a fine approach for cartilage tissue engineering. 8 . On the other hand, the issue of donor availability might be a general drawback when using this juvenile chondrocytes.
Stem cells
Over the years, adult stem cells have been derived from numerous tissues such as the bone marrow, adipose tissue, skin, synovial tissue, periosteum and muscle. Known for its abundant supply, these multipotential cells have shown to regenerate damaged tissues.
Mesenchymal stem cells (MSCs) are being studied extensively. These are adherent, fibroblastic spindleshaped cells that are able to differentiate into other cell types under specific conditions in vitro or in vivo. They express several surface markers, for example, CD29, CD44, CD56, CD90, CD105 and CD166 suggesting that these markers help to differentiate mesenchymal cells from haematopoietic cells. In an earlier study by Johnstone et al. 9 , it was found that bone marrow stem cells undergo chondrogenic differentiation when cultured with transforming growth factor (TGF)-β. They also noted an over expression of collagen X, which is an unwanted up-regulation of the marker of hypertrophy that could lead to cell death. Recently, few studies have reported potential result in the suppression of collagen type X that could restrain the undesired hypertrophy in differentiating MSCs 10, 11 . With regards to cartilage tissue engineering, adipose-derived stem cell has been reported to be capable of undergoing chondrogenic differentiation by producing collagen type II and sulphated glycosaminoglycans in the company of ascorbate, TGF-β and dexamethasone. The potential use of adipose cell is somewhat attractive because liposuction is considered a simple non-invasive procedure than that of bone marrow collection and the human body has relatively abundant subcutaneous fat. However, adipose-derived stem cells have lower chondrogenic potential than bone marrow stem cells.
Meanwhile chondrogenic differentiation using embryonic stem cells is a striking progress in regenerative medicine although it is still in the infancy phase. It has been found that when the cell is co-cultured with primary chondrocytes, it has the potential to differentiate towards the chondrocyte lineage 12 . Although the embryonic stem cell has promising values, their studies are mainly limited in a laboratory setting, in finding answers to the basic biological question rather than being used in the clinical setting. This is partly due to the ethical and social concern and the possibility of unwanted consequences such as potential oncogenic formation since it has unlimited proliferation capability.
Given the current picture, the usage of stem cells be it autologous or allogeneic has indeed become the preferred cell source in cartilage tissue engineering although there is still some uncertainty on their characteristics, while the future of embryonic stem cells has still a long way to go before being considered to be used in the clinical setting.
Biomaterial scaffolds
Scaffolding materials are one of the three major trios for tissue engineering. They can be produced from natural or synthetic products but both have similar characteristics by which a good scaffold should have these desired properties; bioactive, biodegradable, biocompatible, biomimetic and bioresponsive. Although there are many scaffolds being tested, only some are suitable to be used in cartilage tissue engineering.
Natural scaffold
Not only is it cost effective but also because of its biocompatible property for attachments and proliferation of cells natural polymers are ideal as a carrier in cartilage tissue engineering. The most commonly used natural scaffolds include agarose, alginate, chitosan, hyaluronate, collagen and fibrin [13] [14] [15] [16] . Derived from the natural seaweed, agarose and alginate which are polysaccharides are commonly used as a matrix for three dimensional cultures of chondrocytes in vitro. Cells encapsulated in agarose were shown to exhibit chondrogenic differentiation 13 while alginate encapsulation has an effect in maintaining the differentiated phenotype of chondrocytes 14 . However, the fact that both agarose and alginate are not well absorbed by the body may hold back their usage in the clinical setting.
Hyaluronate is a native component in synovial fluid as well as cartilaginous ECM. It has been shown that when chondrocytes are cultured on a hyaluronan-based scaffold (HYAFF 11), collagen type II and aggrecan are expressed while the production of collagen type I are down regulated 17 . Collagen is the natural protein that can be found in bones, cartilages, skin, tendons and other connective tissues in the body. It is one of the most popular scaffolds for cartilage engineering. Collagen has been extensively studied in vitro and in vivo models and studies have shown that when combined with chondrocytes and stem cells, it helps in cartilage growth 18, 19 . Matrix induced ACI which is a special technique adapted from conventional ACI uses a collagen scaffold in place of a periosteal flap. This technique allows seeding of chondrocytes onto the collagen carrier which are then implanted into the defect and secured with fibrin glue.
Review

Compe ng interests: none declared. Confl ict of interests: none declared.
All authors contributed to the concep on, design, and prepara on of the manuscript, as well as read and approved the fi nal manuscript.
All authors abide by the Associa on for Medical Ethics (AME) ethical rules of disclosure.
Licensee Another exciting natural scaffold in the field of cartilage tissue engineering is fibrin 20, 21 . It is desirable as a biomaterial scaffold due to its role in wound repair and tissue reconstruction. Several studies using fibrin glue have been explored to improve cartilage repair 22, 23 and demonstrated that fibrin may be likely to enhance cartilage regeneration.
As the name implies, natural scaffolds are expected to show no foreign material response when implanted in humans. Unfortunately, these natural scaffolds are well known for their poor mechanical properties that need further modifications and there are also concerns of evoking inflammatory response and disease transmission with their usage.
Synthetic scaffolds
Due to the flexibility, versatility and biodegradability, researchers have put great attention to the potential use of synthetic scaffolds in cartilage tissue engineering. The most popular synthetic polymers used in tissue engineering scaffolds include the poly-lactic acid (PLA), poly-glycolic acid (PGA) and poly-lactic-coglycolic acid (PLGA) which is a co-polymer of PLA and PGA. Through various approaches, these polymers are constructed into 3D structures that have a controlled porosity, adjustable degradation rate and proper structure for cell attachment and proliferation. Studies have revealed that PLA and PGA scaffolds showed higher rate of proteoglycan synthesis and chondrocyte proliferation 24, 25 . As a co-polymer of PGA and PLA, PLGA is more stable, has good biocompatibility and biodegradability. It has been suggested that fibrin/PLGA scaffolds may serve as a potential cell delivery and as a structural platform for tissue engineered articular cartilage 15, 16, 26 . It is also interesting to note that PLGA scaffolds that were incorporated with chondrogenic factor TGF-β1 and dexamethasone showed potential chondrogenic differentiation 27 .
Signalling molecules
A wide range of cytokines and growth factors have been studied and reported to promote chondrogenesis including TGF-β, bone morphogenetic protein (BMP), insulin like growth factor (IGF)-1, fibroblast growth factors (FGF) and interleukin-1β. The most sought after of these are the TGF-β and BMP as they favour chondrocyte regeneration. TGF-β is a protein that plays a pivotal role in assisting cartilage regeneration. It was found that TGF-β promotes higher and more effective chondrocyte proliferation and promotes in vitro differentiation of chondrocytes, thus supporting matrix synthesis 28 . One of the isoforms, TGF-β3 also induces cartilaginous ECM production by chondrocytes. Moreover, TGF-β3 was found to stimulate sulphated glycosaminoglycan accumulation 29 . Meanwhile, BMPs belong to the TGF-β superfamily. Out of the 20 BMPs known so far, 8 of them; BMP-1, BMP-2, BMP-4, BMP-5, BMP-7, BMP-8, BMP-9 and BMP-12 are responsible for cartilage restoration. BMP-2 and BMP-9 treatment promotes cartilaginous ECM production and chondrogenic differentiation in MSC 30 . Another study also supports the role of BMP-2, BMP-4 and BMP-7 in promoting in vitro cartilage formation of MSC and stimulates aggrecan synthesis, with BMP-2 being the most effective in obtaining large amounts of cartilage rich proteoglycans 31 . BMPs, TGF-β3 and TGF-β1 when combined together will induce the chondrogenic phenotype in MSC and promote chondrogenesis. Though BMPs showed an important role in restoring articular cartilage in vitro, not many clinical trials are available to validate their usage in humans 32 . However, recent developments have reported that the US Food and Drug Administration have approved the usage of BMP-2 and BMP-7 for human clinical trials 33 . Another growth factor that is important in cartilage integrity is the IGF-1. It has a significant role in the anabolic effect and growth of an organism. In the articular cartilage, IGF-1 was shown to promote a functional collagen network because of the increased collagen and proteoglycan deposition. An interesting study by Jenniskens et al. 34 revealed that when comparing IGF-1, TGF-β2 and FGF-2, IGF-1 showed increased proteoglycan and also collagen deposition thus helping in the formation of a functional collagen network. In the articular cartilage, IGF-1 is the main anabolic growth factor that is involved in cartilage homeostasis, proteoglycan synthesis and breakdown by the chondrocytes 35 . Indeed, the role of growth factors is essential in articular cartilage repair. Their presence is intended to assist in chondrocyte proliferation and proteoglycan synthesis by directing the cells through the correct pathway to achieve native hyaline cartilage formation. The development of techniques using growth factors will continue to move forward with regards to research in cartilage tissue engineering.
Conclusion
Damage to the articular cartilage has remained a vexing predicament. Numerous advancements and strategies have been made to optimise the role of tissue engineering in articular cartilage restoration, but there are still many grey areas that need to be addressed. While current operative treatment modalities are able to restore gross characteristics of the damaged cartilage, the biomechanical and biochemical properties as well as the long-term results are yet to be satisfied. Three major critical concerns with regards to articular cartilage tissue engineering are cell source, choice of scaffold material and appropriate stimulating factors. may vary compared to chondrocytes. Considerable amount of studies have looked into the potential usage of natural and synthetic scaffolds but are still unable to develop scaffolds that could deliver all the required characteristics. Finally, it is still a challenge to find the optimum growth factors needed to promote chondrocyte growth and organisation. Nevertheless, a continuous evolution in cartilage tissue engineering may give a glimpse of hope in the near future and will provide an exciting alternative for a more resilient approach to successfully restore the articular cartilage for the benefit of the human population.
